sorrento

Therapeutics

OnTarget

Jefferies 2016 Healthcare Conference

Henry Ji, PhD - President and CEO

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Disclaimer

NASDAQ: SRNE

Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," "projected" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company's formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's Form 10-K, 10-Q and 8-K reports.

In presenting this material or responding to inquiries in connection with a presentation, management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") as reported in the Company's SEC filings. These results, projections or performance measures are Non-GAAP measures and are not intended to replace or as a substitute for results measured under GAAP, but rather as supplement to the GAAP reported results.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission ("SEC") filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company's filings for a more complete listing of risk factors, contingencies and uncertainties effecting the Company and its business and financial performance.

Sorrento™, G-MAB™, CAR.TNK™, TNK Therapeutics™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Presentation Summary

> Key Technologies

> Sorrento Therapeutics Structure and Programs

> Pipeline Overview

> Other Assets

> Conclusion

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Key Technologies - Antibody Therapeutics - G-MAB Library

Fully Human Antibodies

Highly Successful Screening Hit Rate
(100+ targets screened)

Proprietary Technology
RNA amplification used for library generation

Very High Diversity
2.1×10^{16} *Distinct Antibodies*

Difficult Targets
Small Peptides & Tumor Neo-epitopes



AIP-2

High Value Oncology Targets
PD1, PD-L1, CD123, PSMA, CD47



Most Difficult Targets:
G Protein-Coupled Receptors (GPCRs)



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Key Technologies - Multi-Faceted Immunotherapy Platform



Adoptive Immunotherapy





Immuno-Oncology

ADCs

Antibody Drug Conjugates
Proprietary Toxins
Conjugation Chemistries

Bispecific Abs



Chemical BsAb (CBAs)
IgG-based
Proprietary Biochemistry

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Sorrento Therapeutics Structure



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Programs - Biosimilar / Biobetters (mAbs)

Significant Commercial Opportunities

- Targeting $12 B+ market
- Worldwide market for biosimilar products with Originators' global sales of$100 B+ in 2014
- Four leading biosimilar/ biobetter products have completed Phase 3 trials (in China)
- Significant opportunities for combination therapies

Product	Generic	Target	Brand	2014 Global Sales (US$)
STI-001	Cetuximab	EGFR	Erbitux	$1.9B
STI-002	Infliximab	TNFα	Remicade	$0.9B
STI-003	Basiliximab	CD25	Simulect	$114M
STI-004	Omalizumab	IgE	Xolair	$1.1B



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Programs - Immuno-Oncology mAbs (PD-1 / PDL-1)

Comprehensive Portfolio of Immune Checkpoint mAbs

- STI - A1110 - Targeting PD-1 - Phase: IND-enabling studies
- STI - A1014 - Targeting PD-L1 - Phase: IND-enabling studies
  - China rights licensed to Lee's Pharma
- STI-600 – Targeting TIM3 – Phase: preclinical
- Immuno-oncology Ab Partnerships:
  - Yuhan -> ImmuneOncia JV
  - NantCell -> license of preselected mAb
  - NantCell -> Nantibody JV



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Programs - CAR-T & CAR-pNK - TNK Therapeutics

Asset	Phase
CEA Targeted CAR-T	Phase 1
PSMA Targeted CAR-T	Phase 1
GD3 Targeted CAR-T	Preclinical
IL13R Targeted CAR-T	Preclinical
c-KIT Target CAR-T	Preclinical

Harnessing Adaptive and Innate Immunity



Programs - CAR.TNK - Sorrento

Asset	Phase
PD-LI Targeted CAR.TNK	Preclinical
ROR1 Targeted CAR.TNK	Preclinical

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Programs - CAR-T / CAR.NK Market



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Programs - RTX - Resiniferatoxin

New Paradigm for Treatment of Chronic Pain

- RTX is a non-opioid, highly potent, selective against of the TRPV-1 receptor in development for the treatment of chronic refractory pain associated with advanced cancer

- Completed Phase 1/2 trial with the NIH
  - No unexpected side effects
  - Confirmed activity seen with animal studies

- Potential pivotal phase 2 study targeted for the end of 2016

- Reduces pathological chronic pain without affecting normal pain perception, sensation or muscle function
  - Reducing need for high-dose opioids and lessening severe opioid side effects
  - Avoiding hospitalizations for pain crises and improving quality of life and activity tolerance

- Strong position for complete life cycle management strategy

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Pipeline Overview



** Partnered with NantKwest

* Completed Phase III in China

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Other Assets - LA Cell - Cell-Penetrating Antibody Delivery

Joint Venture and Exclusive License with City of Hope

- Conjugation of antibodies with specifically-modified short oligonucleotides enables efficient cellular internalization, intracellular target recognition
- The ability to modulate intracellular targets with antibody therapeutics will greatly increase druggable space
- Broad range of indications, e.g. oncology, infectious diseases, and inflammation
- Use with other modalities (proteins, peptides, nucleic acids)



(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Other Assets - BiSpecific Abs /ADCs / ARK /Cynviloq

Multiple Additional Assets with Long Term Value Creation Potential

- Combination of C-lock™ and K-lock™ conjugation methods to make multifunctional ADCs, such as dual drug ADCs and Bispecific ADCs
  - Also actively studying the combination of ADCs with immune-oncology therapy as new anti-cancer strategy
- ARK Animal Health - Application of RTX for animal indications (bone and neuropathic pain), Auto-Inducing Peptide (AIP) vaccines for pyroderma and mastitis
- Cynviloq is a polymeric micelle based Cremophor free paclitaxel injected finished formulation
  - In May 2015, entered into a stock sale and purchase agreement with NantPharma for equity interests in IgDraSol (wholly-owned subsidiary and holder of Cynviloq rights) for $90M upfront and up to $620M in potential regulatory milestones and up to $600M in sales milestones

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.

Sorrento Therapeutics - OnTarget

A Comprehensive Immunotherapy Company with Valuable Technologies and Assets

- Recognized leader in antibody technologies
- Comprehensive portfolio of novel immunotherapy technologies
- Clinical-stage biosimilars/biobetter antibodies have substantial market potential
- Unique technologies and strategic relationships to enable meaningful advances in cellular therapies
- Strategic optionality - value creation possibilities across a wide variety of technologies and assets via internal development, licensing and partnering

sorrento

Therapeutics

Contact

Henry Ji, PhD - President and CEO

hji@sorrentotherapeutics.com

(858) 668-6923

Contact

Kevin Herde - EVP and CFO

kherde@sorrentotherapeutics.com

(858) 210-3736

(c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.